Related Experiment Video
Updated: May 16, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Prediction of steroid-sparing agent use in childhood idiopathic nephrotic syndrome
Jérôme Harambat1, Astrid Godron, Sandrine Ernould
1Service de Pédiatrie, Centre de référence Maladies Rénales Rares du Sud Ouest, Centre Hospitalier Universitaire de Bordeaux, Place Amélie Raba Léon, 33076, Bordeaux, France. jerome.harambat@chu-bordeaux.fr
Insights
Identifying children needing steroid-sparing agents (SSA) for idiopathic nephrotic syndrome (INS) is crucial. Achieving first remission quickly predicts the need for SSA in pediatric INS patients.
Area of Science:
- Pediatric Nephrology
- Immunology
- Clinical Trial Design
Background:
- Steroid-sensitive idiopathic nephrotic syndrome (INS) affects many children, with about half developing steroid dependency.
- Prolonged steroid treatment carries adverse effects, necessitating early identification of high-risk patients for steroid-sparing agents (SSA).
Purpose of the Study:
- To identify predictors for the requirement of SSA in children with steroid-sensitive INS.
- To develop a predictive model for tailoring therapeutic strategies in pediatric INS.
Main Methods:
- Retrospective hospital-based cohort study including children with steroid-responsive INS.
- Follow-up duration of at least 4.5 months.
- Cox regression modeling and decision curve analysis were employed.
Main Results:
- Out of 120 children, 72 (60%) required SSA after a median of 10 months.
- Male sex, age at onset, methylprednisolone pulse use, and time to first remission were significant predictors.
- Time to achieve first remission was a strong independent predictor (HR=1.9 as continuous, HR=4.1 when dichotomized at 9 days).
Conclusions:
- Time to first remission is a key predictor for SSA necessity in pediatric INS.
- The developed predictive model demonstrated strong performance (AUC 0.81) and outperformed other strategies.
- Further prospective studies are recommended to validate the prediction model's accuracy and clinical utility.
Background:
About half of children with steroid-sensitive idiopathic nephrotic syndrome (INS) will develop steroid dependency or a frequently relapsing course requiring steroid-sparing agents (SSA). Because of the adverse effects of prolonged steroid treatment, the early identification of children at high risk of requiring SSA may be a useful diagnostic tool to tailor the therapeutic strategy. The aim of this study was to identify predictors of the need for SSA and derive a predictive model.
Methods:
This was a retrospective hospital-based cohort study which included all children with steroid-responsive INS followed for at least 4.5 months. Cox regression modeling and decision curve analysis were performed.
Results:
A total of 120 children (81 boys) with INS were included and followed up for a median time of 6.7 (range 0.4-24.1) years. Median age at diagnosis was 3.4 years. Seventy-two (60 %) children required a SSA after a median time of 10 months following initial diagnosis. Male children, age at disease onset, methylprednisolone pulse use, and time to achieve first remission were significantly associated with the outcome. Time to achieve remission only remained significant after adjustment: hazard ratio (HR) =1.9 [95 % confidence interval (CI) 1.5-2.5] if considered as a continuous variable, and HR=4.1 (95 % CI 1.9-8.6) when dichotomized using the 9-day threshold. The area under the receiver operating curve of the related predictive model was 0.81 (95 % CI 0.74-0.89), and the decision curve analysis demonstrated that this model performed better than any other strategy.
Conclusions:
Time to first remission is a strong predictor of the need for SSA in pediatric INS. Further prospective and impact studies are warranted to confirm the accuracy and benefit of our prediction model.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome I : Introduction
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
